MM&M's pipeline draws from the best drugs in development, profiling 15 agents with the highest approval rating and brightest commercial prospects. These are the prime near-term launch candidates. The report also provides updates on 202 products in a host of theraputic areas.
...
OTHER KEY PRODUCTS IN THE PIPELINE
APRICITABINE Avexa
HIV Infection (Ph. III)
Only other new HIV ART drugs mentioned
Viciviroc Merck
Rilpivirine Tibotec
http://media.mmm-online.com/documents/12/pipeline2010_2759.pdf
2010 provocative agents
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)